Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines.

Morgenstern, Birgit, Michaelis, Martin, Baer, Patrick C, Doerr, Hans Wilhelm, Cinatl, Jindrich (2005) Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochemical and Biophysical Research Communications, 326 (4). pp. 905-8. ISSN 0006-291X. (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:34114)

The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided.

Abstract

Initial in vitro investigations demonstrated type I interferons (IFNs: IFN-alpha, IFN-beta) to inhibit replication of SARS coronavirus (SARS-CoV), but found the nucleoside analogue ribavirin ineffective in Vero cells. In this report, ribavirin was shown to inhibit SARS-CoV replication in five different cell types of animal or human origin at therapeutically achievable concentrations. Since clinical anti-SARS-CoV activity of type I interferons or ribavirin is limited, we investigated the combination of IFN-beta and ribavirin. Determination of the virus yield indicated highly synergistic anti-SARS-CoV action of the combination suggesting the consideration of ribavirin plus IFN-beta for the treatment of SARS.

Item Type:	Article
Subjects:	Q Science > QR Microbiology > QR355 Virology R Medicine > RM Therapeutics. Pharmacology
Divisions:	Divisions > Division of Natural Sciences > Biosciences
Depositing User:	Martin Michaelis
Date Deposited:	05 Jun 2013 20:27 UTC
Last Modified:	16 Nov 2021 10:11 UTC
Resource URI:	https://kar.kent.ac.uk/id/eprint/34114 (The current URI for this page, for reference purposes)

University of Kent Author Information

Michaelis, Martin.

Creator's ORCID:	https://orcid.org/0000-0002-5710-5888
CReDIT Contributor Roles:

Depositors only (login required):

Download Statistics

Total unique views for this document in KAR since July 2020. For more details click on the image.